{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(1)"],"submitter":["Baeuerle PA"],"pubmed_abstract":["T cells expressing CD19-targeting chimeric antigen receptors (CARs) reveal high efficacy in the treatment of B cell malignancies. Here, we report that T cell receptor fusion constructs (TRuCs) comprising an antibody-based binding domain fused to T cell receptor (TCR) subunits can effectively reprogram an intact TCR complex to recognize tumor surface antigens. Unlike CARs, TRuCs become a functional component of the TCR complex. TRuC-T cells kill tumor cells as potently as second-generation CAR-T cells, but at significant lower cytokine release and despite the absence of an extra co-stimulatory domain. TRuC-T cells demonstrate potent anti-tumor activity in both liquid and solid tumor xenograft models. In several models, TRuC-T cells are more efficacious than respective CAR-T cells. TRuC-T ce"],"journal":["Nature communications"],"pagination":["2087"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6504948"],"repository":["biostudies-literature"],"pubmed_title":["Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response."],"pmcid":["PMC6504948"],"pubmed_authors":["Gierut J","Thorausch N","Patel E","Morath A","Hofmeister R","Schamel WW","Ding J","Baeuerle PA","Choudhary R","Kiner O","Scarfo I","Quinn J","Wei Q","Getts D","Horton H","Weiler S","Baldeviano GC","Tavares P","Maus MV","Krishnamurthy J","Le B"],"additional_accession":[]},"is_claimable":false,"name":"Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response.","description":"T cells expressing CD19-targeting chimeric antigen receptors (CARs) reveal high efficacy in the treatment of B cell malignancies. Here, we report that T cell receptor fusion constructs (TRuCs) comprising an antibody-based binding domain fused to T cell receptor (TCR) subunits can effectively reprogram an intact TCR complex to recognize tumor surface antigens. Unlike CARs, TRuCs become a functional component of the TCR complex. TRuC-T cells kill tumor cells as potently as second-generation CAR-T cells, but at significant lower cytokine release and despite the absence of an extra co-stimulatory domain. TRuC-T cells demonstrate potent anti-tumor activity in both liquid and solid tumor xenograft models. In several models, TRuC-T cells are more efficacious than respective CAR-T cells. TRuC-T ce","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 May","modification":"2026-05-07T14:29:33.422Z","creation":"2019-06-06T23:01:39Z"},"accession":"S-EPMC6504948","cross_references":{"pubmed":["31064990"],"doi":["10.1038/s41467-019-10097-0"]}}